Free. Unsubscribe any time.
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. filed 4 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 2 reporting owners, covering 4 transactions and 17,613 shares. 2 carry the SEC's AFF10B5ONE flag; 2 name a plan only in a footnote. No results print is on file in this window, so no interval is measured.
What stands out
- The most recent filing on file, dated 2026-01-05, came on the same day as the one before it (2026-01-05) and reports 4 transactions against 4 in the filing before it.
- The sales it reports total 1,826 shares, 5,204 fewer than the 7,030 in the filing before it.
- Its 4 filings on file run from 2025-01-03 to 2026-01-05, and state one plan adoption date, 2024-04-08.
Trades in Xilio Therapeutics, Inc. 4
- Brennan Kevin M. — 2025-01-02 · S · 1,803 shares
- Frankenfield Christopher James — 2025-01-02 · S · 6,954 shares
- Brennan Kevin M. — 2026-01-02 · S · 1,826 shares
- Frankenfield Christopher James — 2026-01-02 · S · 7,030 shares
Adoption dates in Xilio Therapeutics, Inc. 1
- 2024-04-08 — stated in 4 filings
Results prints in Xilio Therapeutics, Inc. 0
Trades before a print in Xilio Therapeutics, Inc. 0
Interval to Xilio Therapeutics, Inc.’s next reported results date
How the interval and sources are counted →
- 0within 5 days
- 0within 10 days
- —shortest, days
- 4no later print
Adoption dates Xilio Therapeutics, Inc. states
- 2024-04-08 in 4 filings
Filing text: “10b5-1 trading plan adopted by the reporting person on April 8, 2024”
Sources: SEC EDGAR full-text search and the SEC submissions API.